RxDoctor Payments DataLook up a doctor →

Ladly Abraham, MD

Pulmonary Disease · Conway, ARNPI 1972537090

Payments from drug & device makers

$520,726in general payments, 2019–2025

Across 1,460 payments — averaging $356.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$264K
  • GSK$118K
  • Insmed, Inc.$36K
  • United Therapeutics Corporation$19K
  • Sunovion Pharmaceuticals Inc.$19K
  • Boehringer Ingelheim$19K
  • plus $45K from 39 others

What the payments were for

  • Consulting fees$21,0236%
  • Speaking & faculty fees$270,87073%
  • Travel & lodging$47,48513%
  • Food & beverage$30,9358%
  • Education$3960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$520,726 in reported general payments places this provider in the 95th percentile of 102 pulmonary disease providers in Arkansas.

See all pulmonary disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$596,155
Medicare patients
1,488
Services billed
7,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter2,033$1,641,401
OpsumitMacitentan115$1,432,372
UptraviSelexipag36$736,990
Prolastin CAlpha-1-Proteinase Inhibitor52$674,484
Breztri AerosphereBudesonide/Glycopyr/Formoterol771$573,080
OfevNintedanib Esylate36$463,179
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr448$240,191
Stiolto RespimatTiotropium Br/Olodaterol Hcl373$210,960
Breo ElliptaFluticasone/Vilanterol273$131,883
Spiriva RespimatTiotropium Bromide140$86,381
SymbicortBudesonide/Formoterol Fumarate267$85,586
Bevespi AerosphereGlycopyrrolate/Formoterol Fum139$72,984
Albuterol Sulfate HfaAlbuterol Sulfate2,415$65,053
Dupixent PenDupilumab12$48,727
Spiriva HandihalerTiotropium Bromide75$48,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,794$2,169,362151 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$117,694$2,034,4332,808 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$18,897$784,846585 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$264,401$731,6491,177 claims
Grifols USA, LLCProlastin C$1,148$674,48452 claims
PfizerEliquis$50$30,71938 claims
Johnson & JohnsonXarelto$282$8,01812 claims
MerckDulera$214$4,50211 claims
Teva Pharmaceuticals USA, Inc.Proair Respiclick$17,415$2,51437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 pulmonary disease providers in Arkansas.

Other pulmonary disease in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →